Shots:

• The companies enter in a master agreement to design- develop- and commercialize diagnostic tests for therapies Novartis’ therapeutic pipeline
• The collaboration will initially focus on the development of serum neurofilament light chain (NfL) immunoassay for patients with MS and other neurological diseases
• Siemens will leverage its expertise in the development of clinical diagnostic solutions that can run on Siemens’ global population of ADVIA Centaur and Atellica immunoassay platforms designed for use in hospitals- reference laboratories- and specialty laboratories

­ Ref: PRNewswire | Image: Novartis